{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T07:20:51Z","timestamp":1698736851333},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1007\/s11906-002-0070-x","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T20:11:30Z","timestamp":1180123890000},"page":"394-402","source":"Crossref","is-referenced-by-count":10,"title":["Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: Evidence for and against the combination in the treatment of hypertension and proteinuria"],"prefix":"10.1007","volume":"4","author":[{"given":"Niels Holmark","family":"Andersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl Erik","family":"Mogensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"70_CR1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3317\/jraas.2000.035","volume":"1","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE: ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease. J Renin Angiotensin Aldosterone Syst 2000, 1:234\u2013239.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"70_CR2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851\u2013860. This study provides interesting new findings on the effects of the AT2 receptor blockers in hypertension and nephropathy, and will contribute to a change in the recommended treatment principals of both disease entities.","journal-title":"N Engl J Med"},{"key":"70_CR3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","volume":"345","author":"HH Parving","year":"2001","unstructured":"Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870\u2013878. This study also provides interesting new findings on the effects of the AT2 receptor blockers in hypertension and nephropathy.","journal-title":"N Engl J Med"},{"key":"70_CR4","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","volume":"359","author":"LH Lindholm","year":"2002","unstructured":"Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004\u20131010. This study as well provides interesting new findings on the effects of the AT2 receptor blockers in hypertension and nephropathy.","journal-title":"Lancet"},{"key":"70_CR5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995\u20131003. This study too provides interesting new findings on the effects of the AT2 receptor blockers in hypertension and nephropathy, and will contribute to a change in the recommended treatment principals of both disease entities.","journal-title":"Lancet"},{"key":"70_CR6","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1172\/JCI117251","volume":"93","author":"S Kagami","year":"1994","unstructured":"Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431\u20132437.","journal-title":"J Clin Invest"},{"key":"70_CR7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063\u20131068.","journal-title":"J Clin Invest"},{"key":"70_CR8","first-page":"803","volume":"10","author":"AH Meiracker van den","year":"1992","unstructured":"van den Meiracker AH, Manin\u2019t Veld AJ, Admiraal PJ, et al.: Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992, 10:803\u2013812.","journal-title":"J Hypertens"},{"key":"70_CR9","first-page":"H1769","volume":"273","author":"E Balcells","year":"1997","unstructured":"Balcells E, Meng QC, Johnson WH Jr, et al.: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.","journal-title":"Am J Physiol"},{"key":"70_CR10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.HYP.33.6.1399","volume":"33","author":"M Ihara","year":"1999","unstructured":"Ihara M, Urata H, Kinoshita A, et al.: Increased chymasedependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999, 33:1399\u20131405. Novel experimental findings on alternative pathways to formation of angiotensin II.","journal-title":"Hypertension"},{"key":"70_CR11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","volume":"32","author":"NK Hollenberg","year":"1998","unstructured":"Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998, 32:387\u2013392. Interesting contribution to the understanding of ACE escape mechanisms and alternative pathways of the renin-angiotensinaldosterone system.","journal-title":"Hypertension"},{"key":"70_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb03851.x","volume":"31","author":"RJ MacFadyen","year":"1991","unstructured":"MacFadyen RJ, Lees KR, Reid JL: Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol 1991, 31:1\u201313.","journal-title":"Br J Clin Pharmacol"},{"key":"70_CR13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.CIR.89.1.493","volume":"89","author":"VJ Dzau","year":"1994","unstructured":"Dzau VJ, Re R: Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994, 89:493\u2013498.","journal-title":"Circulation"},{"key":"70_CR14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.CIR.90.1.449","volume":"90","author":"H Rakugi","year":"1994","unstructured":"Rakugi H, Wang DS, Dzau VJ, Pratt RE: Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994, 90:449\u2013455.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"70_CR15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/080370501750066444","volume":"10","author":"M Burnier","year":"2001","unstructured":"Burnier M, Maillard M: The comparative pharmacology of angiotensin II receptor antagonists. Blood Press 2001, 10(Suppl 1):6\u201311.","journal-title":"Blood Press"},{"key":"70_CR16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","volume":"355","author":"M Burnier","year":"2000","unstructured":"Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet 2000, 355:637\u2013645.","journal-title":"Lancet"},{"key":"70_CR17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","volume":"103","author":"M Burnier","year":"2001","unstructured":"Burnier M: Angiotensin II type 1 receptor blockers. Circulation 2001, 103:904\u2013912. Provides a solid overview of the angiotensin II type 1 receptor blockers.","journal-title":"Circulation"},{"key":"70_CR18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI117675","volume":"95","author":"Y Nio","year":"1995","unstructured":"Nio Y, Matsubara H, Murasawa S, et al.: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995, 95:46\u201354.","journal-title":"J Clin Invest"},{"key":"70_CR19","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1161\/01.CIR.96.11.3954","volume":"96","author":"N Ohkubo","year":"1997","unstructured":"Ohkubo N, Matsubara H, Nozawa Y, et al.: Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997, 96:3954\u20133962.","journal-title":"Circulation"},{"key":"70_CR20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.HYP.20.6.737","volume":"20","author":"P Janiak","year":"1992","unstructured":"Janiak P, Pillon A, Prost JF, Vilaine JP: Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992, 20:737\u2013745.","journal-title":"Hypertension"},{"key":"70_CR21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1681\/ASN.V1341100","volume":"13","author":"KF Hilgers","year":"2002","unstructured":"Hilgers KF, Mann JF: ACE Inhibitors versus AT(1) Receptor Antagonists in Patients with Chronic Renal Disease. J Am Soc Nephrol 2002, 13:1100\u20131108. Interesting overview. Interesting discussion between the effects of AT1 antagonists and ACE inhibitors.","journal-title":"J Am Soc Nephrol"},{"key":"70_CR22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/01.CIR.92.4.825","volume":"92","author":"M Azizi","year":"1995","unstructured":"Azizi M, Chatellier G, Guyene TT, et al.: Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995, 92:825\u2013834.","journal-title":"Circulation"},{"key":"70_CR23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3109\/10641969709083197","volume":"19","author":"M Azizi","year":"1997","unstructured":"Azizi M, Guyene TT, Chatellier G, Menard J: Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Clin Exp Hypertens 1997, 19:937\u2013951.","journal-title":"Clin Exp Hypertens"},{"key":"70_CR24","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/01.HYP.29.2.634","volume":"29","author":"M Azizi","year":"1997","unstructured":"Azizi M, Guyene TT, Chatellier G, et al.: Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997, 29:634\u2013640.","journal-title":"Hypertension"},{"key":"70_CR25","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200018080-00020","volume":"18","author":"M Azizi","year":"2000","unstructured":"Azizi M, Linhart A, Alexander J, et al.: Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 2000, 18:1139\u20131147.","journal-title":"J Hypertens"},{"key":"70_CR26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0895-7061(00)01304-2","volume":"14","author":"MR Weir","year":"2001","unstructured":"Weir MR, Weber MA, Neutel JM, et al.: Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001, 14:567\u2013572.","journal-title":"Am J Hypertens"},{"key":"70_CR27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.jhh.1001159","volume":"15","author":"R Fagard","year":"2001","unstructured":"Fagard R, Lijnen P, Pardaens K, et al.: A randomised, placebocontrolled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. J Hum Hypertens 2001, 15:161\u2013167.","journal-title":"J Hum Hypertens"},{"key":"70_CR28","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1046\/j.1523-1755.2002.00260.x","volume":"61","author":"C Delles","year":"2002","unstructured":"Delles C, Jacobi J, John S, et al.: Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002, 61:1462\u20131468.","journal-title":"Kidney Int"},{"key":"70_CR29","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/00005344-200006000-00017","volume":"35","author":"GS Stergiou","year":"2000","unstructured":"Stergiou GS, Skeva II, Baibas NM, et al.: Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000, 35:937\u2013941.","journal-title":"J Cardiovasc Pharmacol"},{"key":"70_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000013417","volume":"19","author":"LA Hebert","year":"1999","unstructured":"Hebert LA, Falkenhain ME, Nahman NS Jr, et al.: Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999, 19:1\u20136.","journal-title":"Am J Nephrol"},{"key":"70_CR31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/diacare.25.1.95","volume":"25","author":"K Rossing","year":"2002","unstructured":"Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002, 25:95\u2013100.","journal-title":"Diabetes Care"},{"key":"70_CR32","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1046\/j.1523-1755.2001.00745.x","volume":"59","author":"R Agarwal","year":"2001","unstructured":"Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001, 59:2282\u20132289.","journal-title":"Kidney Int"},{"key":"70_CR33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/ajkd.2002.31392","volume":"39","author":"R Agarwal","year":"2002","unstructured":"Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002, 39:486\u2013492.","journal-title":"Am J Kidney Dis"},{"key":"70_CR34","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","volume":"321","author":"CE Mogensen","year":"2000","unstructured":"Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440\u20131444. st dual blockade trial on hypertension and microalbuminuria in patients with type 2 diabetes mellitus","journal-title":"BMJ"},{"key":"70_CR35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/ajkd.2001.25176","volume":"38","author":"D Russo","year":"2001","unstructured":"Russo D, Minutolo R, Pisani A, et al.: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001, 38:18\u201325.","journal-title":"Am J Kidney Dis"},{"key":"70_CR36","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1046\/j.1523-1755.2000.00432.x","volume":"58","author":"KT Woo","year":"2000","unstructured":"Woo KT, Lau YK, Wong KS, Chiang GS: ACEI\/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000, 58:2485\u20132491.","journal-title":"Kidney Int"},{"key":"70_CR37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00004872-200201000-00018","volume":"20","author":"P Ferrari","year":"2002","unstructured":"Ferrari P, Marti HP, Pfister M, Frey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002, 20:125\u2013130.","journal-title":"J Hypertens"},{"key":"70_CR38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00004872-200204000-00033","volume":"20","author":"ED Berger","year":"2002","unstructured":"Berger ED, Bader BD, Ebert C, et al.: Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 2002, 20:739\u2013743.","journal-title":"J Hypertens"},{"key":"70_CR39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/ndt\/17.4.597","volume":"17","author":"P Kincaid-Smith","year":"2002","unstructured":"Kincaid-Smith P, Fairley K, Packham D: Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002, 17:597\u2013601. Large dual blockade trial on patients with nondiabetic nephropathy. Provides interesting new results.","journal-title":"Nephrol Dial Transplant"},{"key":"70_CR40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004872-200018010-00013","volume":"18","author":"LM Ruilope","year":"2000","unstructured":"Ruilope LM, Aldigier JC, Ponticelli C, et al.: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000, 18:89\u201395. This large dual blockade trial on patients with nondiabetic nephropathy also provides interesting new results.","journal-title":"J Hypertens"},{"key":"70_CR41","first-page":"231","volume":"12","author":"N Nakao","year":"2001","unstructured":"Nakao N, Takada M, Yoshimura A, Ideura T: Combination therapy of ACE inhibitor and A-II receptor blocker more powerfully retards progression of non-diabetic renal failure than monotherapy of each drug. A multicenter, four year double blind randomised trial in Japan. J Am Soc Nephrol 2001, 12:231\u2013231.","journal-title":"J Am Soc Nephrol"},{"key":"70_CR42","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3317\/jraas.2001.020","volume":"2","author":"NH Andersen","year":"2001","unstructured":"Andersen NH, Mogensen CE: Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment. J Renin Angiotensin Aldosterone Syst 2001, 2:146\u2013152.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"70_CR43","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jama.1996.03540080071033","volume":"276","author":"D Rennie","year":"1996","unstructured":"Rennie D: How to report randomized controlled trials. The CONSORT statement. JAMA 1996, 276:649.","journal-title":"JAMA"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-002-0070-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-002-0070-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-002-0070-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T07:14:55Z","timestamp":1628925295000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-002-0070-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1007\/s11906-002-0070-x","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}